US Rheumatologists Believe Biogen’s Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data
12 sept. 2024 16h36 HE
|
Spherix Global Insights
EXTON, PA, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The systemic lupus erythematosus (SLE) advanced treatment landscape is poised for evolution, with multiple new therapies in development to treat this...
EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing
13 déc. 2023 07h00 HE
|
EvolveImmune
Fundraising Includes Strategic Investment by Bristol Myers Squibb Coupled with Support from Existing Investors EvolveImmune Initiates Chemistry, Manufacturing, and Control (CMC) Activities for Lead...
MRTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Mirati Therapeutics, Inc. to Bristol Myers Squibb
20 oct. 2023 09h01 HE
|
Wohl & Fruchter LLP
MONSEY, N.Y., Oct. 20, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Mirati Therapeutics, Inc. (Nasdaq: MRTX) (“Mirati”) to...
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
04 oct. 2022 07h00 HE
|
Autolus Therapeutics plc
- Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option...
TURNING POINT THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of TPTX and Encourages Investors to Contact the Firm
06 juin 2022 14h19 HE
|
Bragar Eagel & Squire
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
Simio Sync 2022: Practical Applications Comes to a Successful Conclusion
10 mars 2022 14h00 HE
|
Simio LLC
PITTSBURGH, March 10, 2022 (GLOBE NEWSWIRE) -- Simio is delighted to announce the successful conclusion of its fifth Simio Sync event titled "Practical Applications". The virtual conference...
Triphase Accelerator Announces Positive Interim Results of Phase 1 Trial of TRPH-222 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
07 déc. 2020 16h30 HE
|
Triphase Accelerator
TORONTO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Triphase Accelerator, a private drug development company dedicated to advancing novel compounds through clinical proof-of-concept, today...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of MyoKardia, Inc. Buyout
05 oct. 2020 21h00 HE
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating MyoKardia, Inc. (“MyoKardia”) (NASDAQ GS: MYOK) regarding possible breaches of...
MYOKARDIA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MYOK and Encourages Investors to Contact the Firm
05 oct. 2020 14h57 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
Global Antidepressant Market: Increased Stress Levels over the Covid-19 Outbreak - PMI
30 juin 2020 10h40 HE
|
PMI
Covina, CA, June 30, 2020 (GLOBE NEWSWIRE) -- The global antidepressant market accounted for US$ 13.2 billion in 2019 and is estimated to be US$ 26.1 billion by 2029 and is anticipated to register a...